Abbott Laboratories (ABT): Gangbangcheon A × Geochajesi 12/20 — CGM Global #1, FreeStyle Libre 7M Users, 52 Consecutive Dividend Increases — Split Entry After Bearish Chart + NEC Lawsuit Resolution
CGM Global #1 (FreeStyle Libre 7M users, $6.8B, $10B 2028 target) + world's first dual-chamber leadless pacemaker + 52 consecutive dividend increases + FCF $7.4B (margin 16.7%). All 5 Gangbangcheon steps pass (Grade A), conservative upside +29%, base +52%. However, NEC lawsuit 760+ cases with bellwether trial (Aug 2026) uncertainty + bearish chart (-35% from 52-week high) → Geochajesi 12/20 watch-and-wait. Entry: 20-day MA volume breakout + NEC outcome confirmed → split entry.
Core Position
CGM Global #1 (FreeStyle Libre 7M users, $10B 2028 target) + world's first dual-chamber leadless pacemaker + 52 consecutive years of dividend growth + FCF $7.4B (16.7% margin) — Gangbangcheon Grade A (all 5 steps pass, conservative upside +29%) × Geochajesi 12/20 watch-and-wait. Split entry after NEC lawsuit bellwether trial (Aug 2026) outcome + 20-day MA breakout confirmed.
Investment Thesis
Abbott Laboratories (ABT) is rated 'high-quality company — await timing' at Gangbangcheon Grade A × Geochajesi 12/20. Business quality is a clear A — CGM global #1 (FreeStyle Libre, 7M users, $6.8B revenue), world's first dual-chamber leadless pacemaker, Alinity diagnostics platform, and Ensure/Similac brands diversified across 4 segments. All 5 Gangbangcheon steps pass (industry growth, market leadership, business model, financials, K-PER upside all satisfied). FCF $7.4B (16.7% margin), 52 consecutive dividend increases, and +29% conservative upside are the justification. Geochajesi 12/20 reflects healthy institutional flows but chart in downtrend (early bounce off $81.97 52-week low) limits timing. NEC lawsuit (760+ cases pending, August 2026 bellwether trial) and Exact Sciences $21B acquisition debt ($20B borrowing, EPS dilution $0.20) are the two core risks. Entry conditions: ① 20-day MA sustained above with volume + ② NEC bellwether result confirmed → split entry. Current $90–95 range offers FY2028-based conservative upside of +29%, making long-term DCA also valid.
① Non-Financial — CGM Triple Moat (Tech + Switching Costs + Cost Structure) + Repeated First-Mover Strategy
FreeStyle Libre's moat is a triple structure: technology (electrochemical sensor patents, FDA PMA), switching costs (LibreView data, app ecosystem, 14-day wear pattern), and cost structure (economies of scale enabling lower pricing vs. Dexcom, penetrating the Type 2 mass market). A 2025 patent cross-license agreement with Dexcom ended the long-running dispute. AVEIR leadless pacemaker (world's first dual-chamber, launched in 50+ countries) and Tendyne TMVR (world's first transcatheter mitral valve replacement, 2025 FDA approval) confirm the repeated 'category creation' pattern. CEO Robert Ford (joined 1996, 26 years, diabetes unit background) is the direct architect of FreeStyle Libre's success — outstanding strategic consistency. 52 consecutive dividend increases (Dividend King level) is the strongest evidence of sustained earnings power. → Full 5-layer analysis, moat types, and competitor breakdown in the Non-Financial tab.
② Validator — Gangbangcheon A (All 5 Steps Pass) × Geochajesi 12/20 = High-Quality Company, Await Timing
Gangbangcheon 5 steps: Step 1 (Industry) ✅ — TAM 5%+ (CGM 17%, structural heart 10–12%); Step 2 (Market Position) ✅ — CGM global #1, leadless pacemaker #1, adult nutrition #1; Step 3 (Business Model) ✅ — consumable recurring revenue + subscription mix, CEO 26-year internal tenure; Step 4 (Financial Quality) ✅ — FCF up 3 consecutive years ($5.1B→$6.4B→$7.4B), Quadrant 1; Step 5 (K-PER) ✅ — conservative +29%. Grade A. Geochajesi 12/20 — Volume/Flows 3, Chart 2, Catalyst 4, Market 3. Exact Sciences acquisition (Grade A catalyst +2) and Libre's 12 consecutive quarters of double-digit growth (+1) defend the Catalyst score of 4. Chart in bearish alignment (capped at 2 pts) is the timing constraint. K-PER scenarios: optimistic +77%, base +52%, conservative +29%. → Full Gangbangcheon steps, 3 K-PER scenarios, and Geochajesi details in the Validator tab.
③ Technical — Post-Downtrend Low Bounce in Early Stage, W-Bottom Forming — Neckline ($96) Breakout is the Real Buy Signal
After a -41% decline from the 52-week high $139.06 (2025) to low $81.97 (March 31, 2026), the stock is in early bounce territory at ~$91. MA alignment: 200-day SMA $96 > 50-day EMA $89 > current price $91 — bearish order. However, bullish RSI divergence (new price low + RSI low of 16 forming higher at 38) = the strongest technical leading reversal signal. W-bottom forming (first low $100–105 + second low $81.97); breakout above neckline $96–100 completes the pattern (target $110–115). Key support: $84–85 (volume cluster), $81.97 (absolute low). Three scenarios: ⓐ recommended — await $84–86 support, R:R 2.5:1 (first target $96); ⓑ 3-tranche $91/$87/$84 average $87.3, R:R 1.9:1 (second target); ⓒ immediate $91 not recommended, R:R 0.5:1 (first target). → Full 3 scenarios, Fibonacci, and RSI in the Technical tab.
Key Metrics
Price (Analysis Date)
~$90.54
2026-06-09 기준
Market Cap
~$157.6B
발행주식 ~1.74B주
FY2025 FCF
$7.4B
FCF 마진 16.7% — 3년 연속 ↑
Geochajesi
12 / 20
강방천 A · 타이밍 관망
K-PER Conservative Target
~$117/주
+29% 업사이드 (FY2028)
52 Consecutive Dividend Increases
$2.36/주
배당 수익률 ~2.1%
Bull Case
- FreeStyle Libre structural growth engine — 7M users, $10B 2028 target (surpassing 15% CAGR), TAM expanding as GLP-1 users increasingly adopt CGM for monitoring. Triple moat (technology, switching costs, cost structure) preserves leadership in Europe and emerging markets against Dexcom competition
- Exact Sciences $21B acquisition — adds Cologuard/Cancerguard cancer diagnostics platform ($60B TAM). Expect $3B additional revenue in FY2026. Cologuard global rollout through Abbott's 160-country commercial network is the long-term TAM expansion driver
- 52 consecutive dividend increases + FCF $7.4B (16.7% margin) — the strongest combination of financial stability. $7B share buyback + dividends pursued simultaneously. Even worst-case NEC lawsuit settlement is absorbable against annual FCF
- All 5 Gangbangcheon steps pass + historically discounted valuation — forward P/E ~18x is 30% below historical 22–25x. FY2028 conservative upside +29%. Long-term trend line support confirmed since 1992. Post-major-M&A recovery track record (St. Jude Medical 2017 → 2018–2019 strength)
- CEO interest alignment + internal development culture — Robert Ford (joined 1996, 26 years, ~$50M personal stock holding, 100% performance-linked pay). Maintained guidance despite tariff headwinds every quarter → demonstrated high-quality earnings visibility. 13th consecutive internally-promoted CEO tradition
Bear Case
- NEC lawsuit 760+ cases — top single risk. August/November 2026 bellwether trials scheduled. Missouri $495M and Illinois $70M verdicts as precedent. Adverse outcome could mean billions in damages. Nutritionals (Similac) business structural restructuring may be unavoidable. Largest unpriced potential shock
- Exact Sciences $21B acquisition debt burden — $20B borrowing + EPS dilution $0.20 confirmed (FY2026). Integration costs + Cologuard global rollout speed uncertain. Rising debt load increases interest rate sensitivity. FY2026 earnings visibility lower
- Chart in bearish alignment + volume-less bounce — 200-day SMA $96 is the first resistance. Bounce since May accompanied by declining volume → possible short-covering with no genuine accumulation. Unfavorable NEC trial outcome could activate Elliott Wave C-leg decline scenario ($75–80)
- Healthcare sector policy headwinds — UnitedHealth shock + US Medicaid cuts + drug price negotiations. Healthcare sector broad YTD underperformance in 2026. Medical devices differentiated in relative terms, but sector de-rating risk remains
- Diagnostics segment structural stagnation — FY2025 -4.3% decline after COVID base effect exhausted. Intensifying competition from Roche and Siemens. Diagnostics segment growth likely to remain sluggish until Cologuard integration
Technical Summary
After a -41% decline from the 52-week high $139.06 (2025) to the low $81.97 (March 31, 2026), the stock is in early bounce territory at ~$91. MA alignment bearish: 200-day SMA ($96) > 50-day EMA ($89) > current price ($91). Bullish RSI divergence (new price low + RSI low forming higher) = the strongest technical leading reversal signal. W-bottom pattern forming; neckline breakout at $96–100 is the pattern completion trigger.
ABT Technical Analysis — Price Structure, Moving Averages, RSI, MACD, Fibonacci
Support
S1: $87~88 (50일 EMA / 단기 피벗 S1), S2: $84~85 (거래량 매물대 / 직전 저점 반등 지점), S3: $81.97 (52주 절대 저점 — 이탈 시 추세 재붕괴)
Resistance
R1: $92~93 (단기 피벗 고점 / 거래량 밀집), R2: $96~97 (200일 SMA / Fib 38.2%), R3: $107~108 (Fib 50%), R4: $120~123 (Fib 61.8% / 주요 매물대)
Trend Analysis
Long-term (200-day SMA $96): Bearish — current price below 200-day MA. Medium-term (50-day EMA $89): Weak → current price just recovering above the 50-day EMA. Short-term (20-day MA ~$87–89): Slight improvement — entering above 20-day MA. MA alignment: bearish order maintained (200>50>price), but price has reclaimed above 50-day EMA — short-term recovery signal within bearish alignment.
Momentum & Indicators
RSI (14) ~48 — neutral zone. From extreme oversold at RSI 16–29 at the March 31, 2026 low → bullish divergence → recovered to 48. RSI 50 line breakout and hold = momentum recovery confirmation. MACD: -0.45 (early June), histogram still negative but sharply narrowing (from -8 trough, major improvement), pre-golden-cross stage. Bollinger Band: upper ~$103 / lower ~$93, band squeezing (imminent breakout direction). Volume: declining volume accompanying post-May bounce → genuine accumulation not confirmed — caution signal.
Key Technical Points
The most critical resistance. Recapturing the 200-day SMA = breaking the W-bottom neckline → pattern completion, technical target $110–115 auto-derived. Doubled resistance with Fib 38.2% ($96) makes it a high-strength zone. Volume-confirmed breakout is the key trend-reversal signal
Overlapping support from volume cluster + prior low bounce. Entry zone for conservative scenario ⓐ. If price retests after breaking below 50-day EMA ($89), R:R 2.5:1 to first target $96. Stop-loss $80.5 (below 52-week low $81.97)
52-week absolute low recorded on March 31, 2026. Breaking below triggers trend collapse confirmation → Elliott Wave C-leg decline ($75–80) scenario activation. Final stop-loss reference for all entry scenarios
Price made a new low ($81.97) + RSI low formed higher than the prior low (RSI 16 vs prior 29 → recovery to 38). Bullish divergence from extreme oversold is the strongest technical leading reversal signal. RSI recovery from 16 to 48 by April further confirms this
Trading Scenarios
Entry
$84–86 (volume cluster + 50-day EMA re-support confirmed)
Stop
$80.5 (below 52-week low $81.97)
Target
T1 $96.0 (+13.9%) / T2 $107.5 (+27.5%) / T3 $121.0 (+43.6%)
Best R:R. Must confirm support touch + bounce. Opportunity cost if price recovers without hitting $84. Confirmation recommended before NEC bellwether trial (Aug 2026)
Entry
$91 (1/3) + $87 (1/3) + $84 (1/3) → average entry $87.3
Stop
$80.5 (-7.8%, below 52-week low)
Target
T1 $96.0 (+10.0%) / T2 $107.5 (+23.1%)
Staged entry with no opportunity-cost risk. R:R only holds if full position held to T2. Confirm in advance that -7.8% stop-loss is acceptable
Entry
Immediate entry at $91
Stop
$80.5 (-11.5%)
Target
T1 $96.0 (+5.5%) / T2 $107.5 (+18.1%) / T3 $121.0 (+33.0%)
T1 R:R 0.5:1 — unsuitable. Valid only if holding to T3 (6–12 months). Insufficient basis for immediate entry amid NEC lawsuit uncertainty
Bullish Signals
20-day MA sustained above + volume 150%+ confirmed (genuine accumulation)
200-day SMA $96 breakout + W-bottom neckline completion → technical target $110–115
NEC lawsuit bellwether (Aug 2026) settlement or favorable verdict → lawsuit uncertainty resolved
Q2 2026 earnings (July 16, 2026) — Exact Sciences integration revenue $3B visible + guidance maintained
RSI 50 line breakout + weekly hold (momentum trend reversal confirmed)
Bearish Risks
Bounce continues without volume → short-covering limit, re-decline risk
NEC bellwether adverse verdict → sharp decline + chart structure invalidated, C-leg ($75–80) activated
$81.97 absolute low broken → trend collapse confirmed, stop-loss triggered
Bollinger Band squeeze breaks to the downside → bearish momentum strengthens
* Technical analysis is based on historical data and does not guarantee future returns. Final investment decisions are your own responsibility.
Abbott Laboratories Growth Metrics and Business Model Dashboard
Switching Cost & Moat
Moat Strength by Type
Technology / Patent
FreeStyle Libre electrochemical sensor patents + FDA PMA (7–12 year entry barrier). 10+ major regulatory approvals in 2024. AVEIR i2i™ wireless tech. Tendyne TMVR world's first.
Switching Costs
LibreView app/data ecosystem + 14-day wear pattern locks in patients. Alinity diagnostics: hospital replacement costs hundreds of millions + retraining + re-certification. Cologuard repeated cancer screening (annual).
Cost Structure / Scale
89 manufacturing facilities providing global economies of scale. CGM sensor pricing below Dexcom, penetrating Type 2 mass market. 6 Libre production sites (including 2 in US) for tariff diversification.
Brand
FreeStyle Libre — Galien Foundation "Best Medical Technology of the Last 50 Years." Ensure adult nutrition global #1. Similac strong B2C brand. Fortune "World's Most Admired Company" list.
Network Effect
Direct network effects limited. However, LibreView user data accumulation → AI glucose prediction improvement → building accuracy advantage over competitors. Lingo (non-diabetic) market expansion potential.
Core moat is FreeStyle Libre's triple composite moat (technology + switching costs + cost structure). Electrochemical sensor technology and FDA PMA patents (7–12 year entry barrier), LibreView app/data ecosystem and 14-day wear pattern (switching costs), economies of scale maintaining lower pricing vs. Dexcom (cost structure). Alinity diagnostics platform has strong switching costs — hospital replacement costs hundreds of millions plus re-certification burden. Overall, technology + brand (medium–strong) + cost structure + switching costs all operating simultaneously.
Management & Governance
CEO Robert B. Ford (took office 2020, joined 1996 with 26 years of tenure, Boston College + UC Berkeley Haas MBA). Progressed from SVP Diabetes Care → EVP Medical Devices → President/COO → CEO; the direct architect of FreeStyle Libre's success. Holds ~417,000 shares (direct + trust, market value ~$50M). 100% performance-linked compensation. Every Abbott CEO has been an internal promotion — a long-standing tradition. Pursuing aggressive yet disciplined capital allocation: 52 consecutive dividend increases + $7B buyback + $21B Exact Sciences acquisition simultaneously. Maintained guidance despite tariff headwinds → high-credibility management.
Competitive Landscape
Dexcom (DXCM)
Duopoly with Abbott in US Type 1 diabetes CGM. G7 competes on accuracy. 2025 cross-license ended long-running dispute. Abbott differentiates via lower pricing, Type 2 mass-market penetration, and Europe leadership.
Medtronic (MDT)
Competes in CGM (Guardian 4) + cardiovascular (pacemakers, structural heart). CGM market 3rd tier vs. Abbott/Dexcom duopoly. Competing with Medtronic Micra in leadless pacing, but Abbott holds dual-chamber technology advantage.
Roche Diagnostics
Global clinical diagnostics market leader. Direct competition with Alinity platform. Abbott diversifying through POC diagnostics and Exact Sciences integration. No CGM presence limits direct threat scope.
Apple (기술 위협)
Developing non-invasive blood glucose monitoring for Apple Watch. Estimated 5–10 years to achieve clinical-grade accuracy. Wellness market (no prescription required) may overlap, but medical-grade CGM replacement is unlikely in medium term.
CGM market: Abbott vs. Dexcom duopoly. Abbott leads Europe and emerging markets (low-price strategy penetrating Type 2 mass market); Dexcom stronger in US Type 1. 2025 patent cross-license ends long-running dispute. Structural heart: MitraClip (pioneer of the mitral valve repair category), Tendyne TMVR (world's first transcatheter mitral replacement, 2025 FDA approval). Leadless pacemaker: AVEIR dual-chamber (world's first, 50+ countries) = effectively monopoly. Diagnostics: three-way competition with Roche and Siemens Healthineers. Apple Watch non-invasive CGM — 5–10 years to clinical-grade accuracy, a medium-term threat.
ESG & Summary
Direct healthcare infrastructure beneficiary — structurally aligned with social demand from aging populations and chronic disease growth (diabetes, cardiovascular). FreeStyle Libre improves diabetes management for 7M people globally. AVEIR leadless pacemaker eliminates lead-related complications. 35 of 89 manufacturing facilities in the US (supporting domestic manufacturing base). 52 consecutive dividend increases = consistent long-term shareholder value. NEC lawsuit (Similac preterm infant risk) is the biggest ESG concern.
Key Risks
NEC Lawsuit — Top Short-Term Risk
760+ cases in MDL. Missouri $495M and Illinois $70M verdicts as precedent. Federal bellwether trials scheduled August/November 2026. Adverse outcome could mean billions in damages. Abbott FCF $7B+ makes one-time absorption possible, but Similac nutritionals business restructuring may be unavoidable. Largest unpriced potential shock.
Exact Sciences Acquisition Debt + Integration Risk
$20B borrowing + EPS dilution $0.20 confirmed (FY2026). Integration costs + Cologuard global rollout speed uncertain. Cancerguard growth below 5% in FY2027 would signal integration failure. Rising debt increases interest rate sensitivity.
Healthcare Sector Policy Headwinds
UnitedHealth shock + US Medicaid cuts + drug price negotiations. Medical devices differentiated in relative terms, but whole-sector de-rating risk. Nutritionals (Similac) and Established Pharma segments directly pressured.
Chart Bearish Alignment + Volume-Less Bounce
Bearish MA alignment persists below 200-day SMA ($96). Post-May bounce with declining volume → possible short-covering with no genuine accumulation. Unfavorable NEC trial could activate Elliott C-leg decline ($75–80).
Gangbangcheon 5/5 passed
Gangbangcheon Grade A — all 5 steps pass. Industry structure, market leadership, business model, financial quality, and K-PER upside (conservative +29%) all satisfied. "Great company, good price — conditional on NEC lawsuit resolution + chart bearish alignment improvement."
Abbott Laboratories 3-Year Financial Quality (FY2023–2025) — Revenue, Operating Income, ROA, ROE Cross Model
Gangbangcheon 5-Step Checklist
Step 1
Industry Analysis ✅
TAM growing 5%+ across all segments: CGM (17% CAGR), structural heart (10–12%), early cancer diagnostics (12–15%), POC diagnostics (7–9%), adult nutrition (5–6%). Direct healthcare infrastructure beneficiary — aging population, chronic disease growth, GLP-1 users adopting CGM expanding TAM. 5 entry barriers satisfied (core patents, regulation, brand, switching costs, economies of scale).
Step 2
Market Position ✅ Grade A
CGM global #1 (leading Europe and emerging markets), leadless pacemaker world #1 (dual-chamber monopoly), adult nutrition (Ensure) global #1, structural heart and clinical diagnostics top 3. Pricing power YES (3/3): price maintained + users grew from 3M to 7M + operating margin improvement simultaneously confirmed.
Step 3
Business Model ✅
Scalability 4/4: LibreView AI glucose prediction (platform expansion), Cologuard global rollout (geographic expansion), AVEIR + data + AI diagnostics vertical integration (vertical expansion), consumable recurring revenue strengthening (subscription-ization). CEO with 26-year internal tenure, 52 consecutive dividend increases, disciplined capital allocation ($7B buyback + $21B Exact Sciences acquisition).
Step 4
Financial Quality ✅
FCF positive and rising 3 consecutive years ($5.1B→$6.4B→$7.4B), FCF margin 16.7% (meets 15%+ threshold), Cross-model Quadrant 1 (revenue growth + operating margin improvement simultaneous). P↑Q↑C→ optimal combination. All forced-D checks clear (BM describable, FCF positive, no market share decline, no fraud/manipulation, no excessive equity issuance).
Step 5
K-PER Upside ✅
Conservative scenario upside +29% (meets 10% safety margin threshold). FY2026 operating income $9.0B as anchor, consensus 8–10% annual growth for 3 years (FY2026→FY2028). Multiple 18–22x (conservatively discounted for lawsuit risk). All forced-D checks clear.
K-PER Scenario Analysis (3-Year Target)
K-PER based on operating income. Abbott's diversified healthcare (devices + diagnostics + nutritionals + pharma) structure makes operating income the core profitability metric. Anchor: FY2026E operating income ~$9.0B (post-Exact Sciences integration, tariff absorption). Multiple: 18–22x for mature quality + high-growth innovation hybrid (10–15% discount vs. industry average for lawsuit risk). Three scenarios based on FY2026→FY2028 consensus 8–10% annual growth. Based on ~1.74B shares outstanding.
| Scenario | Annual Growth | Non-GAAP Profit | Applied PER | Target Cap | Upside |
|---|---|---|---|---|---|
| Optimistic (Consensus High End) | FY26E $9.0B → FY28E +12% CAGR | FY28E OI $12.7B × 22배 | 22x | $279B 시총 → ~$160/주 | +77% |
| Base (Consensus Midpoint) | FY26E $9.0B → FY28E +10% CAGR | FY28E OI $12.0B × 20배 | 20x | $240B 시총 → ~$138/주 | +52% |
| Conservative (Consensus Low End) | FY26E $9.0B → FY28E +8% CAGR | FY28E OI $11.3B × 18배 | 18x | $204B 시총 → ~$117/주 | +29% |
Geochajesi Score (12/20)
Institutional ownership 74%+ maintained. Vanguard (9.3%) and BlackRock (8.2%) passive positions stable. TABR Capital Management new $7.4M entry (Q1 2026), GMO Quality Fund $341M maintained. Goldman Sachs Buy, 20/28 analysts Strong Buy. Intraday volume specific data unavailable → conservative applied.
Bearish MA alignment continues (200>50>current) → full bearish cap applied (max 2 pts). Low bounce from $81.97 confirmed +1, early rising trend signal from low +1. Prior high / 52-week high not yet recaptured, volume-less bounce warning.
Grade A catalysts: Exact Sciences $21B acquisition completed (2026-03-23, entering $60B cancer diagnostics market) +2, Medical Devices 12 consecutive quarters of double-digit growth (Q1 2026 +13.2%) +1. Additional: post-M&A price recovery history (St. Jude 2017 → 2018 strength) +1. Long-term sustained catalysts (Libre $10B target, Exact Sciences multi-year growth) +1 → offset by -1 for weak sector tailwind.
S&P 500 hitting new all-time highs (near 6,980) in early June 2026 +1, Nasdaq bullish bias +1. Healthcare sector YTD broad underperformance (UnitedHealth shock, Medicaid cuts, drug price headwinds). Medical devices relatively differentiated +1. Rate cut expectations partially favorable (conservatively excluded).
Entry Strategy (3 Tranches)
Volume cluster support + 50-day EMA reconfirmation + bullish close. R:R 2.5:1 to T1 $96 / 5.1:1 to T2 $107.5. Stop-loss $80.5 (-5.3%). Confirmation recommended before NEC bellwether trial (Aug 2026).
Staged entry with no opportunity-cost risk. Average $87.3, R:R 2.9:1 to T2 $107.5 (full hold required). Stop-loss $80.5 (-7.8%). Inferior R:R vs. ⓐ but allows partial participation if $84 not reached.
FY2028-based conservative upside +29% secured in this zone. Cost averaging valid for multi-year hold. Caution: avoid maximum weighting before lawsuit uncertainty resolved. Approach as defensive portfolio holding.
Exit Triggers
T1 $96 (200-day SMA / W-bottom neckline) reached → sell 1/3. Hold remainder if volume-confirmed breakout + Geochajesi recovers to 14+
T2 $107.5 (Fib 50%) reached → sell additional 1/3. K-PER base scenario substantially achieved. Re-evaluate holding remainder long-term
NEC lawsuit MDL adverse verdict (billions in damages confirmed) → immediate reassessment, reduce position or stop-loss
$81.97 absolute low broken → stop-loss triggered. Trend collapse confirmed
FreeStyle Libre annual growth below 10% for 3 consecutive quarters → business model damage signal, reduce weighting
Exact Sciences integration failure (FY2027 cancer diagnostics growth below 5%) → reduce weighting
Portfolio Weight Recommendation
Split buy (30–50%) — increase to maximum weight after timing confirmation. Current price $90–95 is within the FY2028 conservative +29% upside zone, making long-term DCA valid. Caution: avoid maximum weighting before NEC lawsuit uncertainty is resolved. Position size ⓐ scenario entry ($84–86) within 1–1.5% total portfolio loss limit.
Editor Note
Abbott is a textbook 'high-quality company — await timing' case at Gangbangcheon A × Geochajesi 12/20. Competitive strength is clear — FreeStyle Libre's triple moat, world's first dual-chamber leadless pacemaker, 52 consecutive dividend increases, FCF $7.4B. K-PER conservative upside +29% also passes. However, the NEC lawsuit (August 2026 bellwether trial) as a clear catalyst risk and bearish chart alignment constrain timing. Smartest approach: ① await $84–86 support entry (R:R 2.5:1) + ② confirm NEC bellwether outcome simultaneously. Resolving either one substantially increases the probability of reaching Geochajesi 14+.
Financial Data
Abbott Laboratories uses a calendar fiscal year (Jan 1–Dec 31). FY2025 complete (revenue $44.3B). FY2026 Q2 in progress (Q1 2026 adjusted EPS $1.15, +6% YoY). Next earnings (Q2 FY2026): July 16, 2026.
| Period | Revenue | Growth | Op. Income | Op. Margin |
|---|---|---|---|---|
| FY2023ROA ~6.7%, ROE ~12.4%, FCF $5.1B (margin 12.7%) — first year post-COVID base effect, diagnostics decline absorbed | $40.1B | — | $6.83B | 17.0% |
| FY2024ROA ~7.3%, ROE ~13.3%, FCF $6.4B (margin 15.2%) — Medical Devices +12.6% growth offset diagnostics decline | $42.0B | +4.7% | $6.83B | 16.3% |
| FY2025ROA ~7.5%, ROE ~13.5%, FCF $7.4B (margin 16.7%) — operating margin 18.2% near all-time high — Quadrant 1 ideal growth profile | $44.3B | +5.7% | $8.05B | 18.2% |
GAAP vs Non-GAAP Note
K-PER applied on operating income basis. Abbott's diversified healthcare group structure (devices + diagnostics + nutritionals + pharmaceuticals) makes operating income the core profitability metric. Anchor: FY2025 operating income $8.05B. Multiple: mature quality + high-growth innovation hybrid (18–22x), conservatively discounted 10–15% below industry average to reflect lawsuit risk. Per-share conversion based on ~1.74B shares outstanding.
Key Valuation Metrics
FCF Trend (FY23→FY25)
$5.1B→$7.4B
FCF margin 12.7%→15.2%→16.7%, rising 3 consecutive years — excellent by Gangbangcheon standard (15%+ threshold met)
Operating Margin Trend
17.0%→16.3%→18.2%
Slight dip in FY24 then recovery to 18.2% in FY25 — structural margin recovery confirmed after full COVID base exhaustion
Adjusted ROA / ROE
7.5% / 13.5%
ROA and ROE both improving (FY23→FY25) = Cross-model Quadrant 1. Adjusted basis (may differ slightly from official reported figures)
Forward P/E (Current Price)
~18배
30% discount vs. historical 22–25x. Historically discounted, reflecting lawsuit risk
Shares Outstanding / Dividend
~1.74B주 / $2.36
52 consecutive dividend increases (Dividend King level), yield ~2.1%. $7B active share buyback program
FY2026 Guidance
EPS $5.38~$5.58
Includes Exact Sciences dilution of $0.20. FY2026 operating income estimate ~$9.0B (consensus-based)
* GAAP basis. All figures are estimates based on public information and are not investment advice.
Same Exchange
- PWRQuanta Services (PWR): Gangbangcheon B × Geochajesi 13/20 — North America Electric Construction #1, 62,000-Person Labor Moat, $48.5B Record Backlog, All K-PER Scenarios Overvalued — Watch-and-Wait
- DEJohn Deere (DE): Gangbangcheon B × Geochajesi 9/20 — North America Ag Machinery #1, Triple Moat, FY2026 Cycle Trough, Watch-and-Wait as Price Exceeds K-PER Base ($469)
- XYLXylem (XYL): Gangbangcheon B × Geochajesi 8/20 — Global Pure-Play Water #1, PFAS & AI Water Demand Structural Tailwinds, Thin Safety Margin at Current Price